Published in Immunology on April 01, 1972
In vitro culture of functional human thymic epithelium. Clin Exp Immunol (1975) 1.02
ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT. J Exp Med (1965) 15.47
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. J Immunol (1967) 8.06
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res (1968) 6.20
Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum. J Immunol (1967) 3.86
A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component. J Immunol (1967) 3.18
In vitro rosette inhibition by antihuman antilymphocyte serum. Correlation with skin graft prolongation in subhuman primates. Transplantation (1969) 3.12
A new in vitro test evaluating anti-lymphocyte serum potency. Transplant Proc (1969) 2.21
Immunosuppressive potency and in-vitro activity of antilymphocyte globulin. Lancet (1969) 2.02
The selective action of antilymphocyte serum on recirculating lymphocytes: a review of the evidence and alternatives. Clin Exp Immunol (1970) 1.76
Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A (1970) 1.63
Histopathological effects in mice of heterologous antilymphocyte serum. J Exp Med (1968) 1.61
Renal transplantation in the inbred rat. 3. A study of heterologous anti-thymocyte sera. J Exp Med (1967) 1.57
ACTION OF THE FIRST COMPONENT OF COMPLEMENT. ACTIVITATION OF C'1 TO C'1A IN THE HEMOLYTIC SYSTEM. J Immunol (1964) 1.45
Effect of antilymphocytic antibody and antibody fragments on skin-homograft survival and the blood-lymphocyte count in rats. Lancet (1967) 1.41
In vitro detection of immunosuppressive activity of anti-lymphocyte sera. Nature (1968) 1.30
Activation of C'1 to C'1 esterase on gel filtration on Sephadex G-200. Studies on normal human serum, euglobulin and hereditary angioneurotic edema serum. Acta Pathol Microbiol Scand (1966) 1.29
[Analytic study of 69 anti-mouse lymphocyte rabbit serums. I. "In vivo" activity]. Pathol Biol (Paris) (1970) 0.96
Immunosuppressive effects of antilymphocyte serum in complement-deficient mice: evidence that immune cytolysis is not essential for ALS activity. J Immunol (1970) 0.94
In vivo and in vitro properties of intact and pepsin-digested heterologous anti-mouse thymus antibodies. J Immunol (1968) 0.87
Immunosuppressive and graft-rejecting anti--bodies in heterologous anti-lymphocytic serum. J Exp Med (1971) 0.83
[Renal allograft in dogs treated with antilymphotyce serum. Comparison between "in vitro" tests and immunodepressive effects of the serum]. Pathol Biol (Paris) (1969) 0.79
[Isolation of lymphocytes from circulating blood of normal and uremic humans]. Rev Fr Etud Clin Biol (1968) 0.77
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry (1966) 15.12
Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature (1996) 8.02
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res (1968) 6.20
In vivo specific antigen recognition by rosette forming cells. Nature (1970) 4.78
In vitro evaluation of immunosuppressive drugs. Nature (1969) 4.70
Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med (1987) 4.38
Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A (1994) 3.77
Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet (1997) 3.68
Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med (2001) 3.56
The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis. J Immunol (1968) 3.24
Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol. J Immunol Methods (1977) 3.24
Appearance of T-cell markers in bone marrow rosette-forming cells after incubation with thymosin, a thymic hormone. Proc Natl Acad Sci U S A (1971) 3.13
The unactivated form of the first component of human complement, C1. Biochem J (1976) 3.12
In vitro rosette inhibition by antihuman antilymphocyte serum. Correlation with skin graft prolongation in subhuman primates. Transplantation (1969) 3.12
The complement system of man. I. N Engl J Med (1972) 3.09
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol (1997) 2.89
Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet (1999) 2.79
Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med (1998) 2.75
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
The isolation and structure of C4, the fourth component of human complement. Biochem J (1977) 2.61
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
T cell-mediated inhibition of the transfer of autoimmune diabetes in NOD mice. J Exp Med (1989) 2.51
Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol (1996) 2.43
The key role of nucleosomes in lupus. Arthritis Rheum (1999) 2.26
A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity (1994) 2.26
A new in vitro test evaluating anti-lymphocyte serum potency. Transplant Proc (1969) 2.21
Studies on thymus products. II. Demonstration and characterization of a circulating thymic hormone. Immunology (1973) 2.17
Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes (1994) 2.17
Langerhans cells: role in contact hypersensitivity and relationship to lymphoid dendritic cells and to macrophages. Immunol Rev (1980) 2.10
Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Genet (1997) 2.08
Interaction of plasma kallikrein with the C1 inhibitor. J Immunol (1970) 2.07
Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol (1990) 1.96
Studies on thymus products. IV. Absence of serum 'thymic activity' in adult NZB and (NZB x NZW) F1 mice. Clin Exp Immunol (1973) 1.93
Isolation, biochemical characteristics, and biological activity of a circulating thymic hormone in the mouse and in the human. Ann N Y Acad Sci (1975) 1.89
Establishment and characterization of a murine hybridoma secreting monoclonal anti-DNA autoantibody. J Immunol (1980) 1.88
Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur J Immunol (1988) 1.87
Evaluation of T-cells and thymic serum factors in man using the rosette technique. Transplant Rev (1973) 1.87
Structural and functional differences between the H-2 controlled Ss and Slp proteins. J Exp Med (1978) 1.85
Transfer of symptomatic peanut allergy to the recipient of a combined liver-and-kidney transplant. N Engl J Med (1997) 1.83
Deficit of suppressor T cells in active multiple sclerosis. Lancet (1980) 1.83
Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med (1992) 1.82
The use of monoclonal anti-T cell antibodies to study T cell imbalances in human diseases. Clin Exp Immunol (1981) 1.82
Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest (1974) 1.81
Peanut agglutinin. I. A new tool for studying T lymphocyte subpopulations. J Immunol (1978) 1.80
Fluid phase destruction of C2hu by C1hu. II. Unmasking by C4ihu of C1hu specificity for C2hu. J Exp Med (1969) 1.78
The structure and enzymic activities of the C1r and C1s subcomponents of C1, the first component of human serum complement. Biochem J (1977) 1.78
A monoclonal anti-DNA antibody also binds to cell-surface protein(s). Proc Natl Acad Sci U S A (1984) 1.75
A gene for hereditary paroxysmal cerebellar ataxia maps to chromosome 19p. Ann Neurol (1995) 1.74
Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients. Arch Neurol (2001) 1.73
Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun (1991) 1.71
Depressed primary in vitro antibody response in untreated systemic lupus erythematosus. T helper cell defect and lack of defective suppressor cell function. J Clin Invest (1980) 1.68
Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am J Med (1978) 1.67
Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. GRAID Research Group. Group for Research on Auto-Immune Disorders. Arthritis Rheum (1999) 1.67
Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups. Hum Mol Genet (1997) 1.65
Thymus dependency of rosette-forming cells: evidence for a circulating thymic hormone. Transplant Proc (1972) 1.63
Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest (1992) 1.63
Antigen recognition by T lymphocytes. II. Similar effects of azathioprine, antilymphocyte serum, and anti-theta serum on rosette-forming lymphocytes in normal and neonatally thymectomized mice. Cell Immunol (1972) 1.62
Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes (1990) 1.57
The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med (1995) 1.56
Pancreatic lesions in AIDS. Lancet (1987) 1.55
Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum (1997) 1.55
Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol (1998) 1.55
The rheumatoid rosette. A diagnostic test unifying seropositive and seronegative rheumatoid arthritis. Am J Med (1970) 1.55
Modulation of function of the activated first component of complement by a fragment derived from serum. I. Effect on early components of complement. J Exp Med (1971) 1.54
In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation (1990) 1.53
Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest (1990) 1.53
Early affect of adult thymectomy. Nat New Biol (1971) 1.53
Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum (2000) 1.52
Staining of Langerhans cells with monoclonal antibodies to macrophages and lymphoid cells. Proc Natl Acad Sci U S A (1983) 1.50
The complement system of man (second of four parts). N Engl J Med (1972) 1.47
Inhibition by epsilon-aminocaproic acid of the activation of the first component of the complement system. J Immunol (1975) 1.46
A neutrophil immobilizing factor derived from human leukocytes. II. Specificity of action on polymorphonuclear leukocyte mobility. J Immunol (1973) 1.45
Immunological aspects of psoriasis. II. Dissociated impairment of thymus-dependent lymphocytes. Br J Dermatol (1976) 1.44
Binding of autologous erythrocytes to immature T-cells. Proc Natl Acad Sci U S A (1975) 1.43
Evaluation of T cell subsets in myasthenia gravis using anti-T cell monoclonal antibodies. Clin Exp Immunol (1981) 1.42
Thymic hormone-containing cells. Characterization and localization of serum thymic factor in young mouse thymus studied by monoclonal antibodies. J Exp Med (1982) 1.42
The complement system of man. 3. N Engl J Med (1972) 1.41
Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J Clin Invest (1986) 1.40
Characterization of facteur thymique sérique (FTS) in the thymus. I. Fixation of anti-FTS antibodies on thymic reticulo-epithelial cells. Clin Exp Immunol (1980) 1.40
Outbreak of trichinosis near Paris. Br Med J (1979) 1.39
Cyclosporin and autoimmune disease. Lancet (1991) 1.39
Immunotherapy in pre-type 1 diabetes mellitus. Diabetologia (1990) 1.39
Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes. J Exp Med (1982) 1.39